Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode
Journal Article
·
· Bioorg. Med. Chem. Lett.
- Pfizer
The work described herein demonstrates the utility of structure-based drug design (SBDD) in shifting the binding mode of an HTS hit from a DFG-in to a DFG-out binding mode resulting in a class of novel potent CSF-1R kinase inhibitors suitable for lead development.
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 1002546
- Journal Information:
- Bioorg. Med. Chem. Lett., Vol. 20, Issue (5) ; 03, 2010; ISSN 0960-894X
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design
First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes
Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine Template
Journal Article
·
Thu May 21 00:00:00 EDT 2009
· J. Biol. Chem.
·
OSTI ID:1002546
+10 more
First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes
Journal Article
·
Wed Jun 29 00:00:00 EDT 2016
· Biochimica et Biophysica Acta - General Subjects
·
OSTI ID:1002546
+5 more
Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine Template
Journal Article
·
Thu Sep 30 00:00:00 EDT 2010
· Chem. Biol. Drug Des.
·
OSTI ID:1002546
+6 more